Can a Teen Get a GLP-1 Through Telehealth? Ages, Consent and Approved Drugs
A teenager can be prescribed a GLP-1 for obesity, but only a few products are approved for that age group, and a typical cash-pay weight-loss website is usually not set up to do it. As of October 2026, the Wegovy injection and liraglutide (Saxenda and its generic) carry obesity indications for ages 12 and up. Zepbound, the Wegovy pill and Foundayo do not. A legitimate telehealth route for a 13- to 17-year-old looks like pediatric care delivered by video, with a parent involved, not a quick online questionnaire.
Key takeaways
- FDA-approved GLP-1 options for adolescent obesity are the Wegovy injection (12 and older) and liraglutide 3 mg (Saxenda or generic, 12 to 17 with weight and BMI criteria).
- Zepbound is not approved for anyone under 18; Lilly's adolescent obesity trials are still running, and one is listed through December 2030.
- Mounjaro is approved for type 2 diabetes in children 10 and older. That is a diabetes indication, not a weight-loss one.
- The American Academy of Pediatrics says clinicians should offer weight-loss medication to adolescents 12 and older with obesity, alongside lifestyle treatment.
- Expect parental consent, a pediatric or obesity-medicine clinician, and regular growth and side-effect monitoring.
Which GLP-1s are approved for teenagers
Approval for adults does not carry over to teenagers. Each label has a pediatric use section that says whether the drug has been studied and approved in children. Here is where things stand as of October 2026:
| Product | Approved for adolescent obesity? | Label details |
|---|---|---|
| Wegovy injection (semaglutide) | Yes, 12 and older | Obesity defined as BMI at or above the 95th percentile for age and sex; 2.4 mg or 1.7 mg weekly maintenance |
| Wegovy tablets | No | Safety and effectiveness not established in pediatric patients |
| Saxenda (liraglutide 3 mg) and generic liraglutide | Yes, 12 to 17 | Body weight above 60 kg and BMI corresponding to 30 for adults by international cut-offs |
| Zepbound (tirzepatide) | No | Safety and effectiveness not established in pediatric patients |
| Foundayo (orforglipron) | No | Safety and effectiveness not established in pediatric patients |
| Mounjaro (tirzepatide) | No (diabetes only) | Approved for type 2 diabetes in patients 10 and older |
| Ozempic (semaglutide) | No | Safety and efficacy not established in pediatric patients |
Source: section 8.4 of the prescribing information for Wegovy, Saxenda, Zepbound, Foundayo, Mounjaro and Ozempic, as of October 2026.
Wegovy injection
The Wegovy label (revised June 2026) supports the adolescent indication with a 68-week trial in 201 patients aged 12 to 17. Teens follow the same step-up schedule as adults, with 2.4 mg weekly as the recommended maintenance dose and 1.7 mg as an alternative. The higher 7.2 mg dose that adults can now reach is not established for pediatric patients, according to the label. The tablet form is adults-only; Novo Nordisk's NovoCare page states it is not known whether Wegovy tablets are safe and effective for people under 18.
Saxenda and generic liraglutide
Liraglutide is a daily injection. The Saxenda label (revised February 2026) bases its pediatric approval on a 56-week trial in 251 patients aged 12 to 17. It includes a stopping rule specific to teens: evaluate BMI after 12 weeks on the maintenance dose and discontinue if BMI has not dropped at least 1% from baseline. Teva launched a generic version of Saxenda on August 28, 2025, with the same adolescent indication (patients who weigh more than 60 kg), as Fierce Pharma reported.
Zepbound: still in trials for teens
The Zepbound label (revised August 2026) states that safety and effectiveness have not been established in pediatric patients. Lilly is running Phase 3 studies in teens. One, NCT06075667, is registered on ClinicalTrials.gov as a study of once-weekly tirzepatide in adolescents who have obesity, or overweight with weight-related conditions. Another, SURMOUNT-ADOLESCENTS-2 (NCT06439277), is listed on Lilly's trial site as enrolling, with a goal of 300 participants aged 12 to 17 and dates running to December 2030. Until results are submitted and FDA approves a pediatric indication, any Zepbound prescription for a teen would be off-label.
Mounjaro for teens with type 2 diabetes
Mounjaro, the diabetes brand of tirzepatide, now has a pediatric indication. FDA's review of the supplemental application, completed November 26, 2025, recommended approval for glycemic control in patients 10 and older with type 2 diabetes, with a pediatric maximum of 10 mg weekly. The current Mounjaro label reflects that age floor. The Pediatric Endocrine Society's update describes it as an adjunct to diet and exercise to lower A1c in young people with type 2 diabetes. It is not an obesity indication.
Looking at telehealth for an adult in the family?
Compare current adult GLP-1 programs, and check each one's age policy, licensing and terms directly.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
What pediatric guidelines say
In January 2023, the American Academy of Pediatrics published its first comprehensive guideline on evaluating and treating obesity in children and adolescents. According to the AAP's announcement, it says physicians should offer adolescents 12 and older with obesity weight-loss medication, paired with lifestyle treatment and based on each drug's indications, risks and benefits. Teens 13 and older with severe obesity should be evaluated for metabolic and bariatric surgery.
The guideline treats medication as an add-on, not a replacement. The full guideline in Pediatrics describes intensive health behavior and lifestyle treatment as at least 26 hours of nutrition, physical activity and behavior-change lessons over 3 to 12 months, ideally face to face and involving the whole family. A program that only ships medication is not delivering what the guideline describes.
Why most online weight-loss platforms won't treat a 15-year-old
Many direct-to-consumer GLP-1 programs are built around adults: the clinicians, intake forms and pricing assume an adult patient who consents for themselves. Check a platform's terms of service for its minimum age before filling out anything. There are good reasons a platform may limit itself to adults:
- Several popular drugs are adults-only. Zepbound, the Wegovy pill and Foundayo have no pediatric indication.
- Consent works differently. State law generally requires a parent or guardian to consent to a minor's routine medical care, and rules vary by state.
- Licensing still applies. HHS notes that telehealth clinicians must be licensed or legally permitted to practice in the state where the patient is located (telehealth.hhs.gov).
- Teens need growth-aware monitoring. Pediatric obesity is defined by BMI percentiles for age and sex, not adult BMI cut-offs, and the Saxenda 12-week BMI check shows that pediatric dosing has its own rules.
What a legitimate pediatric telehealth pathway looks like
Telehealth can still be part of good care for a teenager. It just looks different from adult programs. A sound setup usually includes:
- The right clinician. A pediatrician, adolescent medicine specialist, pediatric endocrinologist or obesity-medicine clinician who treats adolescents.
- A parent or guardian on the account who consents and joins visits.
- An in-person component. Height, weight and vital signs measured accurately, often through the teen's regular pediatrician.
- Baseline evaluation. Medical history, family history and any labs the clinician decides are needed.
- Lifestyle treatment alongside medication, in line with the AAP guideline.
- A follow-up plan covering side effects, growth, mood and when to stop, such as the Saxenda 12-week rule.
A checklist for parents
| Question | Why it matters | What to do |
|---|---|---|
| Is the drug approved for my teen's age? | Only the Wegovy injection and liraglutide have adolescent obesity indications | Ask the clinician to name the indication; if off-label, ask why |
| Who is the prescriber? | Pediatric experience matters for dosing and growth | Ask for the clinician's name and specialty; check their state license |
| Is my teen's regular pediatrician involved? | Accurate measurements and records live there | Ask how records will be shared |
| What happens if it doesn't work or isn't tolerated? | Labels include stopping rules | Ask for the plan in writing |
| Is it a compounded product? | FDA says compounded drugs are not FDA approved | Ask whether an FDA-approved option fits instead |
Sources: product labels listed above; FDA on unapproved GLP-1 drugs (updated October 1, 2026).
Hypothetical scenarios
These are illustrations, not real families.
Hypothetical A: A 14-year-old's pediatrician has measured a BMI above the 95th percentile and refers the family to a pediatric weight-management clinic that offers video follow-ups. The clinic discusses the Wegovy injection, parents consent, and visits mix in-person measurements with telehealth check-ins. This is telehealth used inside a pediatric care plan.
Hypothetical B: A 17-year-old finds an online program advertising tirzepatide and tries to sign up alone. A properly run adult platform should stop at the age check. If it doesn't, that tells you how carefully the rest of the intake is reviewed.
Where this guide stops
This page explains approvals, guidelines and what to look for in a provider. It cannot tell you whether your teen should take a GLP-1, which one, or at what dose. Those decisions belong to a clinician who examines your child and knows their history.
Researching adult GLP-1 telehealth?
Compare participating providers for adults, then verify each one's licensing, pharmacy and terms directly.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Frequently asked questions
Which GLP-1 drugs are FDA-approved for teenagers with obesity?
As of October 2026, the Wegovy injection is approved for ages 12 and older with obesity, and liraglutide 3 mg (Saxenda or its generic) is approved for ages 12 to 17 who weigh more than 60 kg and meet BMI criteria.
Is Zepbound approved for teens?
No. The Zepbound label says safety and effectiveness have not been established in pediatric patients. Lilly's Phase 3 adolescent trials are still running; SURMOUNT-ADOLESCENTS-2 is listed as enrolling, with dates through December 2030.
Is Mounjaro approved for kids?
Mounjaro is approved for type 2 diabetes in patients 10 and older. That is a blood sugar indication, not an approval for weight loss in teens without diabetes.
Can my teenager sign up for an online GLP-1 program alone?
A minor's routine medical care generally requires a parent or guardian's consent under state law, and many adult-focused platforms set an adult minimum age in their terms. A legitimate pediatric pathway involves a parent, a clinician experienced with adolescents, and ongoing monitoring.
What does the American Academy of Pediatrics recommend?
The AAP's 2023 guideline says physicians should offer weight-loss medication to adolescents 12 and older with obesity, alongside intensive health behavior and lifestyle treatment, and evaluate teens 13 and older with severe obesity for bariatric surgery.
Sources
- Wegovy (semaglutide) injection and tablets prescribing information, Novo Nordisk (revised June 2026)
- Saxenda prescribing information, Novo Nordisk (revised February 2026)
- Zepbound prescribing information, Eli Lilly (revised August 2026)
- Foundayo prescribing information, Eli Lilly (revised July 2026)
- Mounjaro prescribing information, Eli Lilly (revised August 2026)
- Ozempic prescribing information, Novo Nordisk (revised May 2026)
- NovoCare: Wegovy product and savings page
- Fierce Pharma: Teva launches first generic GLP-1 for obesity (August 28, 2025)
- ClinicalTrials.gov: Tirzepatide once weekly in adolescents with obesity or overweight (NCT06075667)
- Eli Lilly Clinical Trials: SURMOUNT-ADOLESCENTS-2 (NCT06439277)
- FDA multi-disciplinary review, Mounjaro sNDA 215866/S-039 (pediatric type 2 diabetes)
- Pediatric Endocrine Society: Mounjaro (tirzepatide) approved in pediatrics (February 2026)
- American Academy of Pediatrics: First comprehensive guideline on evaluating and treating children and adolescents with obesity (January 9, 2023)
- American Academy of Pediatrics. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. Pediatrics, 2023
- HHS telehealth.hhs.gov: Getting started with licensure
- FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss (updated October 1, 2026)
Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.